Related Experiment Video
Updated: Aug 8, 2026

10:47
Immuno-fluorescence Assay of Leptospiral Surface-exposed Proteins
Published on: July 1, 2011
Typing leptospira from the perspective of a reference laboratory
1N.H. Swellengrebel Laboratory of Tropical Hygiene, Royal Tropical Institute, Amsterdam.
Summary
The traditional serovar classification for Leptospira, based on cross agglutination absorption tests (CAAT), is becoming outdated. Restriction enzyme analysis (REA) of leptospiral DNA is a valuable supplementary typing method.
Area of Science:
- Microbiology
- Bacteriology
- Epidemiology
Background:
- Leptospirosis is caused by diverse Leptospira variants.
- The serovar classification system, defined by cross agglutination absorption tests (CAAT), has recognized approximately 200 serovars for decades.
- The serovar concept faces limitations in defining epidemiologically significant entities and CAAT is cumbersome for routine use.
Purpose of the Study:
- To evaluate the current Leptospira classification system.
- To explore alternative and supplementary methods for Leptospira typing.
- To propose recommendations for Leptospira classification and typing.
Main Methods:
- Cross agglutination absorption tests (CAAT) for serovar definition.
- Analysis of leptospiral DNA fragment length after digestion with restriction enzymes (REA) for typing.
- Review of various experimental antigenic and genetic analysis methods.
Main Results:
- The serovar concept is increasingly recognized as insufficient for defining epidemiologically important Leptospira entities.
- CAAT is time-consuming and cumbersome for routine Leptospira typing.
- Restriction enzyme analysis (REA) has proven useful for Leptospira typing and can supplement existing methods.
Conclusions:
- New genomic analysis methods are expected to become paramount for Leptospira classification.
- Pending the development of superior typing methods, the current serovar system should be maintained.
- Restriction enzyme analysis (REA) should be incorporated into the description of new serovars.

